Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.
Jade Biosciences (JBIO) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is JBIO's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.
● Seeking AlphaNov 16, 2026 · 12:22 ET
Jade Biosciences, Inc. (JBIO) Presents at UBS Global Biopharma Conference 2026 Transcript
Jade Biosciences, Inc. ( JBIO ) UBS Global Biopharma Conference 2026 November 16, 2026 7:00 AM EST Company Participants Tom Frohlich - President, CEO & Director Andrew King - President of Research & Development Conferenc…
● GlobeNewsWireNov 13, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026 JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the sec…
● GlobeNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class…
● GlobeNewsWireOct 21, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026 JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing st…
● GlobeNewsWireSep 30, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β binding and greater fun…
Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerages
Jade Biosciences, Inc. (NASDAQ: JBIO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, MarketBeat reports. One equities researc…
● GlobeNewsWireSep 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-clas…
Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA re…
Article counts from the last market-wide feed page, across every symbol we track and not just JBIO · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.